Special Issue

Beyond the Negative Assessment: Interval Cervical Cancers and CIN3 Detection Following Negative Cervical Cancer Screening or Colposcopies

Message from the Guest Editor

This Special Issue aims to highlight the epidemiological, clinical, molecular and morphological evidence on residual risk of interval cervical cancer or CIN3 lesions within HPV-based screening programs. We welcome original research articles and reviews addressing: (i) the epidemiology of interval cervical cancer and CIN3 after negative HR-HPV-based screening or an otherwise negative assessment (cytology/colposcopy), (ii) the management and follow-up of women with persistent HR-HPV who repeatedly test negative on cytology/colposcopy, (iii) blind reviews of negative cytological and colposcopic cases with a subsequent diagnosis of CIN3+ lesions, (iv) second-level biomarkers for risk stratification (e.g., viral/host DNA methylation, p16/Ki67 dual staining, extended or complete HPV genotyping) and (v) predictive models for optimizing surveillance intervals within organized screening protocols.

Guest Editor

Dr. Cristina Sani

Regional Laboratory of Cancer Prevention, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50139 Florence, Italy

Deadline for manuscript submissions

30 June 2027

Cancers

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed

mdpi.com/si/292382

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers